Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: A systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 20, Issue 4, 2017, Pages 361-377

  Rowles, J L ^a   Ranard, K M ^a   Smith, J W ^a,b   An, R ^a   Erdman, J W ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYCOPENE; CAROTENOID;

ADVANCED CANCER; CANCER PREVENTION; CANCER RISK; DIETARY INTAKE; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREND STUDY; BLOOD; DIET THERAPY; DOSE RESPONSE; MALE; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR;

CAROTENOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 85029610103     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2017.25     Document Type: Review

References (130)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386.
2. Wan L, Tan HL, Thomas-Ahner JM, Pearl DK, Erdman JW Jr, Moran NE et al. Dietary tomato and lycopene impact androgen signaling-and carcinogenesisrelated gene expression during early TRAMP prostate carcinogenesis. Cancer Prev Res 2014; 7: 1228-1239.
3. Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A et al. Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. Am J Clin Nutr 2015; 102: 1142-1157.
4. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999; 91: 317-331.
5. Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007; 99: 1074-1085.
6. Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and disease. Mol Aspects Med 2005; 26: 459-516.
7. Story EN, Kopec RE, Schwartz SJ, Harris GK. An update on the health effects of tomato lycopene. Annu Rev Food Sci Technol 2010; 1: 189-210.
8. Wang YL, Cui R, Xiao YY, Fang JM, Xu Q. Effect of Carotene and Lycopene on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies. PLoS ONE 2015; 10: e0137427.
9. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004; 13: 340-345.
10. Chen JY, Song Y, Zhang LS. Lycopene/tomato consumption and the risk of prostate cancer: a systematic review and meta-analysis of prospective studies. J Nutr Sci Vitaminol 2013; 59: 213-223.
11. Chen P, Zhang W, Wang X, Zhao K, Negi DS, Zhuo L et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Medicine 2015; 94: e1260.
12. Moher D, Liberati A, Tetzlaff J, Altman DGGroup P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605.
15. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. Brit Med J 1997; 315: 1533-1537.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
17. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses. Stat Med 2010; 29: 1282-1297.
18. Chen H, Manning AK, Dupuis J. A method of moments estimator for random effect multivariate meta-analysis. Biometrics 2012; 68: 1278-1284.
19. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61: 991-996.
20. Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-1055.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Brit Med J 1997; 315: 629-634.
22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
23. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
24. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 1301-1309.
25. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006; 6: 40-57.
26. Almushatat AS, Talwar D, McArdle PA, Williamson C, Sattar N, O'Reilly DS et al. Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer. Int J Cancer 2006; 118: 1051-1053.
27. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 2003; 92: 375-378. discussion 378.
28. Clark PE, Hall MC, Borden LS Jr, Miller AA, Hu JJ, Lee WR et al. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 2006; 67: 1257-1261.
29. Freeman VL, Meydani M, Yong S, Pyle J, Wan Y, Arvizu-Durazo R et al. Prostatic levels of tocopherols, carotenoids, and retinol in relation to plasma levels and self-reported usual dietary intake. Am J Epidemiol 2000; 151: 109-118.
30. Gann PH, Deaton RJ, Rueter EE, van Breemen RB, Nonn L, Macias V et al. A phase ii randomized trial of lycopene-rich tomato extract among men with high-grade prostatic intraepithelial neoplasia. Nutr Cancer 2015; 67: 1104-1112.
31. Jenab M, Ferrari P, Mazuir M, Tjonneland A, Clavel-Chapelon F, Linseisen J et al. Variations in lycopene blood levels and tomato consumption across European countries based on the European prospective investigation into, cancer and nutrition (EPIC) study. J Nutr 2005; 135: 2032S-2036S.
32. Kim HS, Bowen P, Chen LW, Duncan C, Ghosh L, Sharifi R et al. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer Int J 2003; 47: 40-47.
33. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008; 167: 925-934.
34. Kucuk O, Sarkar FH, Sakr W, Khachik F, Djuric Z, Banerjee M et al. Lycopene in the treatment of prostate cancer. Pure Appl Chem 2002; 74: 1443-1450.
35. Mariani S, Lionetto L, Cavallari M, Tubaro A, Rasio D, De Nunzio C et al. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J Mol Sci 2014; 15: 1433-1440.
36. McMillan DC, Talwar D, Sattar N, Underwood M, O'Reilly DS, McArdle C. The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours. Clin Nutr 2002; 21: 161-164.
37. Mohanty NK, Saxena S, Singh UP, Goyal NK, Arora RP. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol 2005; 23: 383-385.
38. Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Metabolomic analysis of prostate cancer risk in a prospective cohort: the alphatocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer 2015; 137: 2124-2132.
39. Niclis C, Diaz MD, Eynard AR, Roman MD, La Vecchia C. Dietary Habits and Prostate Cancer Prevention: A Review of Observational Studies by Focusing on South America. Nutr Cancer Int J 2012; 64: 23-33.
40. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Men who consume vegetable oils rich in monounsaturated fat: their dietary patterns and risk of prostate cancer (New Zealand). Cancer Causes Control 2000; 11: 609-615.
41. Parsons JK, Newman V, Mohler JL, Pierce JP, Paskett E, Marshall J. The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer. Urology 2008; 72: 633-637.
42. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Humphrey P et al. A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemp Clin Trials 2014; 38: 198-203.
43. Rao AV, Fleshner N, Agarwal S. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study. Nutr Cancer 1999; 33: 159-164.
44. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between serum concentrations of micronutrients and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey. Urology 2004; 64: 504-509.
45. Schwenke C, Ubrig B, Thurmann P, Eggersmann C, Roth S. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study. J Urol 2009; 181: 1098-1103.
46. Sporn MB, Liby KT. Is lycopene an effective agent for preventing prostate cancer? Cancer Prev Res 2013; 6: 384-386.
47. van Breemen RB, Sharifi R, Viana M, Pajkovic N, Zhu DW, Yuan L et al. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prev Res 2011; 4: 711-718.
48. van Die MD, Bone KM, Emery J, Williams SG, Pirotta MV, Paller CJ. Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials. BJU Int 2016; 22: 13361.
49. Venkitaraman R, Thomas K, Grace P, Dearnaley DP, Horwich A, Huddart RA et al. Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance. Tumour Biol 2010; 31: 97-102.
50. Al-Delaimy WK, van Kappel AL, Ferrari P, Slimani N, Steghens JP, Bingham S et al. Plasma levels of six carotenoids in nine European countries: report from the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2004; 7: 713-722.
51. Andersson SO, Wolk A, Bergstrom R, Giovannucci E, Lindgren C, Baron J et al. Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 1996; 68: 716-722.
52. Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 2004; 93: 1139-1150.
53. Donaldson MS. A carotenoid health index based on plasma carotenoids and health outcomes. Nutrients 2011; 3: 1003-1022.
54. Hackshaw-McGeagh LE, Perry RE, Leach VA, Qandil S, Jeffreys M, Martin RM et al. A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality. Cancer Causes Control 2015; 26: 1521-1550.
55. Hardin J, Cheng I, Witte JS. Impact of consumption of vegetable, fruit, grain, and high glycemic index foods on aggressive prostate cancer risk. Nutr Cancer 2011; 63: 860-872.
56. Haseen F, Cantwell MM, O'Sullivan JM, Murray LJ. Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis 2009; 12: 325-332.
57. Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 25-34.
58. Ilic D, Forbes Kristian M, Hassed C. Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev 2011; 11: CD008007.
59. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D et al. A tomatobased, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology 2007; 69: 289-294.
60. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005; 65: 2498-2504.
61. Bosetti C, Micelotta S, Dal Maso L, Talamini R, Montella M, Negri E et al. Food groups and risk of prostate cancer in Italy. Int J Cancer 2004; 110: 424-428.
62. Eichholzer M, Stahelin HB, Ludin E, Bernasconi F. Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: seventeen-year follow-up of the prospective basel study. Prostate 1999; 38: 189-198.
63. Fontana CML, Rincon GMR, Lombino DM, Recupero ALU, Elizalde RFP, Laur JDL. Body mass index and diet affect prostate cancer development. Actas Urologicas Espanolas 2009; 33: 741-746.
64. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795-804.
65. Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H et al. The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev 2007; 8: 422-428.
66. Salem S, Salahi M, Mohseni M, Ahmadi H, Mehrsai A, Jahani Y et al. Major dietary factors and prostate cancer risk: a prospective multicenter case-control study. Nutr Cancer Int J 2011; 63: 21-27.
67. Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 2008; 138: 49-53.
68. Zhang J, Dhakal IB, Lang NP, Kadlubar FF. Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control 2010; 21: 1437-1444.
69. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 2000; 10: 361-369.
70. Vance TM, Wang Y, Su LJ, Fontham ETH, Steck SE, Arab L et al. Dietary total antioxidant capacity is inversely associated with prostate cancer aggressiveness in a population-based study. Nutr Cancer Int J 2016; 68: 214-224.
71. Ohno Y, Yoshida O, Oishi K, Okada K, Yamabe H, Schroeder FH. Dietary beta-carotene and cancer of the prostate-a case-control study in Kyoto, Japan. Cancer Res 1988; 48: 1331-1336.
72. Umesawa M, Iso H, Mikami K, Kubo T, Suzuki K, Watanabe Y et al. Relationship between vegetable and carotene intake and risk of prostate cancer: the JACC study. Br J Cancer 2014; 110: 792-796.
73. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767-1776.
74. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002; 94: 391-398.
75. Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM et al. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr 2016; 103: 851-860.
76. Jian L, Du CJ, Lee AH, Binns CW. Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer 2005; 113: 1010-1014.
77. Huang HY, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 2003; 157: 335-344.
78. Agalliu I, Kirsh VA, Kreiger N, Soskolne CL, Rohan TE. Oxidative balance score and risk of prostate cancer: results from a case-cohort study. Cancer Epidemiol 2011; 35: 353-361.
79. Antwi SO, Steck SE, Su LJ, Hebert JR, Zhang H, Craft NE et al. Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate 2016; 76: 1053-1066.
80. Bosetti C, Talamini R, Montella M, Negri E, Conti E, Franceschi S et al. Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy. Int J Cancer 2004; 112: 689-692.
81. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92: 61-68.
82. Deneo-Pellegrini H, De Stefani E, Ronco A, Mendilaharsu M. Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br J Cancer 1999; 80: 591-597.
83. Goodman M, Bostick RM, Ward KC, Terry PD, van Gils CH, Taylor JA et al. Lycopene intake and prostate cancer risk: effect modification by plasma antioxidants and the XRCC1 genotype. Nutr Cancer 2006; 55: 13-20.
84. Hodge AM, English DR, McCredie MR, Severi G, Boyle P, Hopper JL et al. Foods, nutrients and prostate cancer. Cancer Causes Control 2004; 15: 11-20.
85. Jain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancer 1999; 34: 173-184.
86. Jian L, Lee AH, Binns CW. Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr 2007; 16: 453-457.
87. Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer 1997; 76: 678-687.
88. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 92-98.
89. Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2010; 172: 566-577.
90. Lewis JE, Soler-Vila H, Clark PE, Kresty LA, Allen GO, Hu JJ. Intake of plant foods and associated nutrients in prostate cancer risk. Nutr Cancer Int J 2009; 61: 216-224.
91. Lu QY, Hung JC, Heber D, Go VL, Reuter VE, Cordon-Cardo C et al. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 749-756.
92. McCann SE, Ambrosone CB, Moysich KB, Brasure J, Marshall JR, Freudenheim JL et al. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 2005; 53: 33-41.
93. Meyer F, Bairati I, Fradet Y, Moore L. Dietary energy and nutrients in relation to preclinical prostate cancer. Nutr Cancer 1997; 29: 120-126.
94. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Prostate cancer and dietary carotenoids. Am J Epidemiol 2000; 151: 119-123.
95. Park SY, Haiman CA, Cheng I, Park SL, Wilkens LR, Kolonel LN et al. Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes Control 2015; 26: 1507-1515.
96. Parker AS, Cerhan JR, Putnam SD, Cantor KP, Lynch CF. A cohort study of farming and risk of prostate cancer in Iowa. Epidemiology 1999; 10: 452-455.
97. Sanderson M, Coker AL, Logan P, Zheng W, Fadden MK. Lifestyle and prostate cancer among older African-American and Caucasian men in South Carolina. Cancer Causes Control 2004; 15: 647-655.
98. Schuurman AG, Goldbohm RA, Brants HA, van den Brandt PA. A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes Control 2002; 13: 573-582.
99. Shahar S, Shafurah S, Hasan Shaari NS, Rajikan R, Rajab NF, Golkhalkhali B et al. Roles of diet, lifetime physical activity and oxidative DNA damage in the occurrence of prostate cancer among men in Klang Valley, Malaysia. Asian Pac J Cancer Prev 2011; 12: 605-611.
100. Stram DO, Hankin JH, Wilkens LR, Park S, Henderson BE, Nomura AM et al. Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study (United States). Cancer Causes Control 2006; 17: 1193-1207.
101. Wang Y, Jacobs EJ, Newton CC, McCullough ML. Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study-II Nutrition Cohort. Int J Cancer 2016; 2: 30027.
102. Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ et al. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst 2014; 106: djt430.
103. Beilby J, Ambrosini GL, Rossi E, de Klerk NH, Musk AW. Serum levels of folate, lycopene, beta-carotene, retinol and vitamin E and prostate cancer risk. Eur J Clin Nutr 2010; 64: 1235-1238.
104. Chang S, Erdman JW Jr, Clinton SK, Vadiveloo M, Strom SS, Yamamura Y et al. Relationship between plasma carotenoids and prostate cancer. Nutr Cancer 2005; 53: 127-134.
105. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999; 59: 1225-1230.
106. Gill JK, Franke AA, Steven Morris J, Cooney RV, Wilkens LR, Le Marchand L et al. Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F (2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control 2009; 20: 1161-1171.
107. Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003; 12: 518-526.
108. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 1990; 82: 941-946.
109. Karppi J, Kurl S, Nurmi T, Rissanen TH, Pukkala E, Nyyssonen K. Serum lycopene and the risk of cancer: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) study. Ann Epidemiol 2009; 19: 512-518.
110. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 2007; 86: 672-681.
111. Kristal AR, Till C, Platz EA, Song X, King IB, Neuhouser ML et al. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2011; 20: 638-646.
112. Nomura AM, Stemmermann GN, Lee J, Craft NE. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1997; 6: 487-491.
113. Nordstrom T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X et al. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 2016; 76: 339-348.
114. Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested casecontrol study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007; 16: 962-968.
115. Vogt TM, Mayne ST, Graubard BI, Swanson CA, Sowell AL, Schoenberg JB et al. Serum lycopene, other serum carotenoids, and risk of prostate cancer in US Blacks and Whites. Am J Epidemiol 2002; 155: 1023-1032.
116. Wu K, Erdman JW Jr., Schwartz SJ, Platz EA, Leitzmann M, Clinton SK et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13: 260-269.
117. Zhang J, Dhakal I, Stone A, Ning B, Greene G, Lang NP et al. Plasma carotenoids and prostate cancer: a population-based case-control study in Arkansas. Nutr Cancer 2007; 59: 46-53.
118. Michels KB. The role of nutrition in cancer development and prevention. Int J Cancer 2005; 114: 163-165.
119. Jenab M, Slimani N, Bictash M, Ferrari P, Bingham SA. Biomarkers in nutritional epidemiology: applications, needs and new horizons. Hum Genet 2009; 125: 507-525.
120. Moussa M, Landrier JF, Reboul E, Ghiringhelli O, Comera C, Collet X et al. Lycopene absorption in human intestinal cells and in mice involves scavenger receptor class B type I but not Niemann-Pick C1-like 1. J Nutr 2008; 138: 1432-1436.
121. van Bennekum A, Werder M, Thuahnai ST, Han CH, Duong P, Williams DL et al. Class B scavenger receptor-mediated intestinal absorption of dietary betacarotene and cholesterol. Biochemistry 2005; 44: 4517-4525.
122. Tyssandier V, Reboul E, Dumas JF, Bouteloup-Demange C, Armand M, Marcand J et al. Processing of vegetable-borne carotenoids in the human stomach and duodenum. Am J Physiol Gastrointest Liver Physiol 2003; 284: G913-G923.
123. Stratton J, Godwin M. The effect of supplemental vitamins and minerals on the development of prostate cancer: a systematic review and meta-analysis. Fam Pract 2011; 28: 243-252.
124. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996; 88: 1550-1559.
125. Druesne-Pecollo N, Latino-Martel P, Norat T, Barrandon E, Bertrais S, Galan P et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 2010; 127: 172-184.
126. Wei MY, Giovannucci EL. Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening era. J Oncol 2012; 2012: 271063.
127. Borel P, Desmarchelier C, Nowicki M, Bott R. Lycopene bioavailability is associated with a combination of genetic variants. Free Radic Biol Med 2015; 83: 238-244.
128. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol 2013; 10: 38-48.
129. van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M et al Towards an optimal interval for prostate cancer screening. Eur Urol 2012; 61: 171-176.
130. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2016CA Cancer J Clin 2016; 66: 7-30.